Tenax Therapeutics said it will extend its Phase 3 clinical development of an oral form of levosimendan for pulmonary hypertension and heart failure with preserved ejection fraction (PH-HFpEF). Tenax ...
After hours: February 28 at 6:50:53 p.m. EST ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback